Article in BioWorld: Adrecizumab shows apparent mortality benefit in septic shock trial

16. September 2020

September 2020,
by Cormac Sheridan

Download

Contact Info

  • +49 (0) 3302 20 77 8 0
  • +49 (0) 3302 20 77 8 15
  • info@adrenomed.com
  • ADRENOMED AG

Neuendorfstraße 15A 
Hennigsdorf b. Berlin 
D-16761, Germany.

Twitter Linkedin
Google Maps

By loading the map, you agree to Google's privacy policy.
Learn more

Load map

PGlmcmFtZSBsb2FkaW5nPSJsYXp5IgoJCQkJCXNyYz0iaHR0cHM6Ly9tYXBzLmdvb2dsZS5jb20vbWFwcz9xPU5ldWVuZG9yZnN0cmElQzMlOUZlJTIwMTVBJTJDJTIwMTY3NjElMjBIZW5uaWdzZG9yZiYjMDM4O3Q9bSYjMDM4O3o9MTUmIzAzODtvdXRwdXQ9ZW1iZWQmIzAzODtpd2xvYz1uZWFyIgoJCQkJCXRpdGxlPSJOZXVlbmRvcmZzdHJhw59lIDE1QSwgMTY3NjEgSGVubmlnc2RvcmYiCgkJCQkJYXJpYS1sYWJlbD0iTmV1ZW5kb3Jmc3RyYcOfZSAxNUEsIDE2NzYxIEhlbm5pZ3Nkb3JmIgoJCQk+PC9pZnJhbWU+

© 2024 AdrenoMed AG | Imprint/Impressum | Legal Notice/Datenschutzerklärung | Expanded Access Policy